Printed from Voxsanity (voxsanity.com.au) — NCT07239596 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Kidney Cancer
Phase 2 Kidney Cancer Trial, Recruiting
NCT07239596
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old (including those who are exactly 18 or 75)
- People who are willing to take part and sign a consent form agreeing to join the study
- People with a good general health and activity level, able to carry out normal daily activities with little or no restriction (confirm with trial site — this refers to an ECOG score of 0–1)
- People expected to live for at least 3 months or more
- People who have been diagnosed with kidney cancer — specifically a type called clear cell renal cell carcinoma — that has either spread to other parts of the body or cannot be removed with surgery, confirmed through a tissue or cell sample test
- People who are able to provide a sample of their tumour tissue for testing
- People who have at least one area of cancer in the body that can be measured or assessed using standard imaging methods
- People whose bone marrow, liver, kidneys, and other organs are functioning well enough to meet the study's health requirements (confirm with trial site)
Who may not be able to join:
- People who have previously used or are currently using a type of drug called a HIF inhibitor
- People who received chemotherapy, immunotherapy, targeted therapy, anti-tumour traditional Chinese medicine, or any other trial drug within the 4 weeks before starting the study, or who received palliative radiotherapy within 2 weeks before starting
- People who received a live attenuated vaccine (a type of vaccine made with a weakened live virus) within a specific period before starting the study, or who are expected to need one during treatment (confirm with trial site for exact timeframe)
- People who had major surgery within a specific period before starting the study, or who are expected to need major surgery during the study — not including procedures done only to make a diagnosis (confirm with trial site for exact timeframe)
- People who have serious digestive system problems that could affect how the body takes in or absorbs the study drug
- People who have had another active cancer within the past 3 years, or who currently have another cancer at the same time
- People who have had an organ transplant in the past, except for corneal (eye) transplants
- People who had a significant blood clot or blockage in a blood vessel within the 6 months before starting the study
- People who have heart-related symptoms or conditions that are not well managed
- People with active tuberculosis (TB)
- People with significant fluid build-up in the abdomen, chest, or around the heart that is causing symptoms or is not controlled
- People who still have side effects from previous cancer treatments that have not recovered to a mild or resolved level (confirm with trial site — this refers to NCI-CTCAE grade 1 or below)
- People with currently active hepatitis B or hepatitis C infection
- People who, in the judgement of the treating doctor running the trial, have other circumstances that could affect the study results or make it unsafe for them to continue
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: +021-61053363
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Registry
ClinicalTrials.gov
Start date
6 January 2026
Est. completion
1 December 2030
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Dose-limiting toxicity (DLT); Overall response rate(ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.